Edition:
United Kingdom

Profile: Assembly Biosciences Inc (ASMB.OQ)

ASMB.OQ on NASDAQ Stock Exchange Global Select Market

12.67USD
20 Aug 2019
Change (% chg)

$-0.03 (-0.24%)
Prev Close
$12.70
Open
$12.68
Day's High
$12.68
Day's Low
$12.67
Volume
1,161
Avg. Vol
101,098
52-wk High
$40.71
52-wk Low
$11.50

Assembly Biosciences, Inc., incorporated on October 7, 2005, is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. The Company has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. The Company's Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice (cGMP) conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections (CDI). Using its microbiome platform, the Company is developing additional product candidates for multiple indications, including other gastrointestinal indications, metabolic disorders, immunotherapy, and autoimmune diseases.

The Company focuses on the HBc, a viral structural protein that has no human homologue and is involved in various aspects of the HBV lifecycle. The Company's clinical strategy encompasses testing CpAMs as monotherapy and in combination. Using the GEMICEL delivery platform, the Company intends to deliver selected combinations of monoculture strains of beneficial bacteria in synthetic formats to the GI tract. The Company's primary indication is recalcitrant CDI, and it intends to leverage its Microbiome program into various other areas of relevance to gut microbiome disorders, including other infectious disease and GI disorders; indications in oncology, diabetes, obesity and other metabolic disorders, and central nervous system (CNS) disorders.

The Company competes with Seres Therapeutics, Inc., Merck & Co, Inc., Johnson & Johnson, Novartis International AG, Abbvie Inc., Takeda, Bristol Myers Squibb Co. and Pfizer Inc.

Company Address

Assembly Biosciences Inc

11711 N Meridian St Ste 310
CARMEL   IN   46032-4549
P: +1212.5544388
F: +1646.7065101

Company Web Links